Revance to Host Investor Day on September 19, 2023
Rhea-AI Summary
Revance Therapeutics to host Investor Day on September 19, 2023
Positive
Investor Day event may generate positive investor sentiment
08/22/2023 - 08:00 AM
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.
Interested parties can attend the live webcast for the event by registering on the Events and Presentation section
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers in the U.S. , and value-added services including the OPUL® Relational Commerce platform for aesthetic practices.
Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China .
Revance is headquartered in Nashville, Tenn. , with additional office locations in Newark and Irvine, Calif. Learn more www.revance.com www.RevanceAesthetics.com www.DAXXIFY.com www.hcp.daxxifytherapy.com LinkedIn
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822424203/en/
Investors
jessica.serra@revance.com
laurence@gilmartinir.com
Media
sfahy@revance.com
Source: Revance Therapeutics, Inc.
RVNC Rankings
#5006 Ranked by Stock Gains
RVNC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Nashville
About RVNC
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
